Firstly, our cohort exhibited a high prevalence of cardiovascular co-morbidities such as coronary artery disease and heart failure, necessitating the use of guideline-directed medical therapies (GDMTs) like beta-blockers, angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB), or statins. This evidence concerns the gene ACE and coronary artery disorder.